His big break.

Recent News

‘Modelmaxxing’ Replaces ‘Tokenmaxxing’ for Firms Grappling With AI Costs

Photo illustration by Connor Lin / The Daily Upside

5 min read
Even Wealthy Retirement Savers Are Losing the Battle Against Everyday Bills

Photo by Alexander Grey via Unsplash

2 min read
Clients Make Assumptions About Retirement. They’re Often Wrong

Photo by Getty Images via Unsplash

2 min read

JUST FOR FUN

His big break.

DO NOT steal this man's camera time https://t.co/zn5Mlq6awj pic.twitter.com/UL0ArCfKbl
— CJ Fogler account may or may not be notable (@cjzero) June 18, 2024

Photo via Daniel Torok/White House/Newscom

Energy

Saudi Nuclear Deal Confusion Threatens Billions in Potential US Manufacturing Sales

Most likely to benefit is Westinghouse, whose AP1000 nuclear reactor, capable of powering small cities, is at the center of the deal.

1 min read
Photo via Lev Radin/ZUMAPRESS/Newscom

Industrials

Defense Contractors Amass Record Backlogs as Military Spending Ramps Up

The Trump administration has asked for a 44% increase in military spending in 2027, bringing the Pentagon budget near $1.5 trillion.

2 min read

Photo via Richard B. Levine/Newscom

Private Equity

Blackstone’s AI Bet Fuels Blowout Growth While Rivals Grapple With “Zombie Funds”

Blackstone’s secret? Selling the one thing that’s hot: infrastructure for the vast artificial intelligence boom.

2 min read
Photo by Goh Rhy Yan via Unsplash

ETF Upside

Think Twice Before Asking AI About Clients’ Estate Planning

If you wouldn’t share client data with a stranger or a hostile attorney, don’t upload it into generic AI chatbot tools.

2 min read

Photo by Djkeddie via CC BY-SA 4.0

Advisor Upside

Schwab Earnings Boosted by Latest Tax-Focused Strategy

Executives said the firm’s 21% year-over-year revenue growth in the second quarter was partly due to RIAs’ continued interest in long-short strategies.

1 min read
Photo via Sipa USA/Newscom

Healthcare

Trump’s 100% Tariffs on Generic Meds Threaten Headaches at Drugstore Checkouts

Generic drugmakers have much thinner margins, and are less interested in “reshoring” to the US where the costs are higher.

2 min read

Sign Up for The Daily Upside to Unlock This Article

Sharp news & analysis on finance, economics, and investing.